Speaker
Description
Breast cancer is an outrageous metabolic ailment affecting women both globally and nationally. The conventional chemotherapeutic agents are administered in combination (drug cocktails) to target the multiple 2-8 pathways responsible for survival of cancer cells. The other drawbacks include non-specificity, higher toxicity, parenteral route of administration, etc. that make the treatment regimen patient incompliant and tiresome. The concept of polypharmacology (single molecule-multiple critical targets) has been introduced since the past two decades in the treatment of chronic illnesses, including mammary carcinogenesis. The use of small molecules (MW<500 Daltons) has been incorporated in polypharmacology that are facilitated by their small size to interact with both intracellular and extracellular (ligand binding) proteins playing vital roles in cancer initiation, progression, survival, metastasis and inhibition of apoptosis. These molecules provide target specificity, targeting multiple molecular pathways, lower toxicity, oral administration bringing in patient compliance and ease of dosage regimen over conventional treatment. Synthesis of novel chemotherapeutic agents possessing potent anti-neoplastic potential is greatly required. Compounds having Azomethine group (-C=N-) are easy to synthesize by condensation between aldehyde and amines. Since, water is the sole byproduct in the reaction, it can be considered environment friendly. Many studies have reported that anti-cancer activity of Azomethine containing compounds on various cancer cell lines (breast, lung, prostate cancer, etc.) with remarkable potency and inhibitory potential. More advanced research on in vivo cancer models needs to be conducted to evaluate their potency on a biological and molecular level.